Trials / Unknown
UnknownNCT05059912
CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma
Humanized CD7 CAR T-cell Therapy for R/R CD7+ T Cell Lymphoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- The First Affiliated Hospital of Soochow University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, open-label, multiple center and single arm phase 2 study to evaluate the efficacy and safety of T cells expressing humanized CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7 positive T cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Humanized CD7 CAR-T cells | Patients will receive infusion of CAR T-cells targeting CD7 to confirm the safety and efficacy of CD7 CAR T-Cells in CD7+ relapsed or refractory T cell lymphoma |
Timeline
- Start date
- 2021-08-05
- Primary completion
- 2023-08-03
- Completion
- 2024-08-03
- First posted
- 2021-09-28
- Last updated
- 2021-09-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05059912. Inclusion in this directory is not an endorsement.